Investor Relations - News & Events

News & Events

Date	Title
03/05/10	Researchers Report that Thymosin beta 4 Improves Neurological Function after Stroke
03/02/10	RegeneRx Biopharmaceuticals' President and CEO to Present at 22nd Annual Roth Capital Growth Stock Conference
02/26/10	Researchers Report Novel Biological Properties of Fragments of Thymosin Beta 4
02/08/10	Researchers Report Elevated Levels of TB4 Levels Predict Patient Survival in Hepatitis B Virus-related Liver Failure
02/05/10	Researchers Report that TB4 Increases Skeletal Muscle and May Have a Role in the Treatment of Duchenne Muscular Dystrophy
01/21/10	RegeneRx Biopharmaceuticals, Inc. Moving to New Corporate Office Space
01/12/10	NIH Awards Over $5,000,000 for TB4 Research in 2009/2010
12/09/09	RegeneRx Announces Final Clinical Results from Phase I Trial with RGN-352
10/02/09	Promising Clinical Data with RegeneRx's TB4 Drug Candidates Presented on Second Day of Thymosin Meeting
10/02/09	Promising Clinical Data with RegeneRx's Tβ4 Drug Candidates Presented on Second Day of Thymosin Meeting
10/01/09	Scientists Report Impressive Research Results with TB4 on First Day of Thymosin Meeting
10/01/09	Scientists Report Impressive Research Results with Tβ4 on First Day of Thymosin Meeting
09/30/09	RegeneRx Announces Offerings of Common Stock in Aggregate Amount of $4.7 Million
09/29/09	RegeneRx's TB4 Significantly Improves Functional Recovery in Multiple Sclerosis Animal Model
09/29/09	RegeneRx's Tβ4 Significantly Improves Functional Recovery in Multiple Sclerosis Animal Model
09/24/09	RegeneRx Biopharmaceuticals to Present Several Papers at Second International Symposium on Thymosins in Health and Disease
09/04/09	RegeneRx President and CEO to Speak at Rodman & Renshaw Annual Global Investment Conference
08/24/09	RegeneRx Receives Notice of Allowance in Europe for Key Patent Related to Inhibition and Reversal of Skin Aging
06/29/09	NYSE Amex Accepts RegeneRx Plan of Compliance
06/22/09	RegeneRx Working with U.S. Military to Test Tβ4 Against Exposure to Chemical Agents in the Eye
06/12/09	RegeneRx Receives Australian Patent for Compositions and Methods for Delivering Tβ4 and Its Analogues and Derivatives
05/04/09	RegeneRx Receives Australian Patent for Treating Eye Disorders with Tβ4
04/30/09	RegeneRx Receives Listing Notice from NYSE Amex
04/13/09	Tβ4 Identified as Key Molecule Capable of Triggering Stem Cells to Repair Damaged Adult Heart
04/13/09	RegeneRx Announces Financing Transaction and Cost Reduction Program
04/02/09	Ophthalmology Times Publishes Article on RGN-259 and Corneal Wound Healing
03/26/09	RegeneRx Reports Phase II Venous Stasis Trial Results